Literature DB >> 19466541

CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.

Jinhua Xu1, Dezheng Huo, Yinghua Chen, Chika Nwachukwu, Cindy Collins, Janelle Rowell, Dennis J Slamon, Olufunmilayo I Olopade.   

Abstract

To understand the mechanism of transcriptional down-regulation of BRCA1 by promoter methylation, we screened 51 breast cancer cell lines and identified HCC38 as another BRCA1 promoter-methylated cell line in addition to UACC3199. There was low expression of BRCA1 mRNA and BRCA1 protein in both cell lines as measured by quantitative RT-PCR and western blot analysis. After transient treatment with 5-aza-2'-deoxycytidine (5-aza-CdR) and trichostatin A (TSA), re-expression of BRCA1 mRNA and BRCA1 protein was detected in UACC3199 cells, but not in HCC38 cells. Another demethylating agent, zebularine, did not induce BRCA1 re-expression in either cell line. To test the hypothesis that methylation of CpG sites may affect accessibility of the BRCA1 promoter to transcription factors and consequently cause down-regulation of BRCA1, we analyzed the binding of four transcription factors (CTCF, Sp1, E2F1 and E2F6) to the BRCA1 promoter using chromatin immunoprecipitation assay (ChIP) and quantitative PCR. CTCF and E2F1 were enriched at the unmethylated BRCA1 promoter in MCF-7 cells. In contrast, these two transcription factors were not enriched at the methylated BRCA1 promoter in UACC3199 and HCC38 cells. Following demethylating drug treatment, E2F1 was enriched at the BRCA1 promoter in the demethylated UACC3199 cells. This indicates that reduced accessibility of transcription factors to the methylated promoter is one of the mechanisms for down-regulation of BRCA1 in heavily methylated cancer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19466541      PMCID: PMC6697119          DOI: 10.1007/s10549-009-0422-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

1.  The anti-tumor effects of Mfn2 in breast cancer are dependent on promoter DNA methylation, the P21Ras motif and PKA phosphorylation site.

Authors:  Yufeng Li; Wenyue Dong; Xijin Shan; Hui Hong; Yan Liu; Yankun Liu; Xiaohui Liu; Xiaojun Zhang; Jinghua Zhang
Journal:  Oncol Lett       Date:  2018-03-21       Impact factor: 2.967

2.  β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.

Authors:  Jinhua Xu; Yinghua Chen; Dezheng Huo; Andrey Khramtsov; Galina Khramtsova; Chunling Zhang; Kathleen H Goss; Olufunmilayo I Olopade
Journal:  Mol Carcinog       Date:  2015-02-08       Impact factor: 4.784

Review 3.  The dual lives of bidirectional promoters.

Authors:  Clay Wakano; Jung S Byun; Li-Jun Di; Kevin Gardner
Journal:  Biochim Biophys Acta       Date:  2012-02-21

Review 4.  Beyond the histone tale: HP1α deregulation in breast cancer epigenetics.

Authors:  Johan Vad-Nielsen; Anders Lade Nielsen
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 5.  Chromatin insulators: a role in nuclear organization and gene expression.

Authors:  Jingping Yang; Victor G Corces
Journal:  Adv Cancer Res       Date:  2011       Impact factor: 6.242

6.  Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.

Authors:  Eddy H J van Roon; Noël F C C de Miranda; Merlijn P van Nieuwenhuizen; Emile J de Meijer; Marjo van Puijenbroek; Pearlly S Yan; Tim H-M Huang; Tom van Wezel; Hans Morreau; Judith M Boer
Journal:  Eur J Hum Genet       Date:  2010-12-08       Impact factor: 4.246

7.  c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells.

Authors:  Yinghua Chen; Jinhua Xu; Stanley Borowicz; Cindy Collins; Dezheng Huo; Olufunmilayo I Olopade
Journal:  BMC Cancer       Date:  2011-06-13       Impact factor: 4.430

8.  Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns.

Authors:  Sabrina A Bardowell; Joel Parker; Cheng Fan; Jamie Crandell; Charles M Perou; Theresa Swift-Scanlan
Journal:  Breast Cancer Res Treat       Date:  2013-11-10       Impact factor: 4.872

9.  Functional deficiency of NBN, the Nijmegen breakage syndrome protein, in a p.R215W mutant breast cancer cell line.

Authors:  Bianca Schröder-Heurich; Natalia Bogdanova; Britta Wieland; Xiaoxi Xie; Monika Noskowicz; Tjoung-Won Park-Simon; Peter Hillemanns; Hans Christiansen; Thilo Dörk
Journal:  BMC Cancer       Date:  2014-06-13       Impact factor: 4.430

10.  Dose-dependent activation of putative oncogene SBSN by BORIS.

Authors:  Daria Gaykalova; Rajita Vatapalli; Chad A Glazer; Sheetal Bhan; Chunbo Shao; David Sidransky; Patrick K Ha; Joseph A Califano
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.